ABLYNX (ABLYF) Downgraded by Zacks Investment Research to “Hold”
Zacks Investment Research cut shares of ABLYNX (OTCMKTS:ABLYF) from a buy rating to a hold rating in a report published on Friday morning.
According to Zacks, “Ablynx NV is a biopharmaceutical company which engaged in the development of Nanobodies (R) proprietary therapeutic proteins based on single-domain antibody fragments. The company also discovers and develops therapeutic for inflammation, haematology, immuno-oncology, oncology and respiratory disease. Ablynx NV is headquartered in Ghent, Belgium. “
Separately, Bank of America started coverage on shares of ABLYNX in a research report on Friday, November 10th. They issued a buy rating and a $26.00 price objective on the stock.
Ablynx NV, a biopharmaceutical company, develops Nanobodies that is a proprietary therapeutic protein based on single-domain antibody fragments for the treatment of various diseases. The company develops products in various therapeutic areas, such as inflammation, hematology, immuno-oncology, oncology, and respiratory diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for ABLYNX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABLYNX and related companies with MarketBeat.com's FREE daily email newsletter.